SLT as standard for first-line IOP lowering

In an analysis of almost 2,000 eyes treated with selective laser trabeculoplasty as primary therapy for glaucoma, mean IOP decreased 29% and the cumulative probability of success at 10 years was 90%. » Read more

Novel glaucoma drug rivals standard therapy

Latanoprostene bunod is a probable new drug for the treatment of glaucoma that seems to be well tolerated and potent in lowering IOP. » Read more

Extended release drugs are the next generation medical therapy

To determine which types of topical medications are best for patients, ophthalmologists need to look into what is truth and what is inaccurate regarding preservatives. » Read more

3 strategies for managing traumatic cataract in children

There are several vital components surgeons need to take into consideration when treating children who have traumatic cataracts. » Read more

Argument against subthreshold laser for DME

Efficacy and practical limitations of subthreshold laser treatment for diabetic macular edema. » Read more

VA loss, RNFL thinning characterize MS

Visual loss and progressive thinning of the retinal nerve fiber layer (RNFL) occur over time in patients with multiple sclerosis (MS), according to results from a longitudinal study.» Read more

Downloads

You are subscribed to the Ophthalmology Times Issue Alert.

• When fixed-combination is a viable option

• Controlling circadian IOP fluctuation

• A non-invasive look at trabecular meshwork

• Extended release drugs are the next generation medical therapy